Cerus to Present Cryoprecipitate Comparison Study in Liver Transplantation at 2026 AABB Meeting

By Public Technologies
  • Cerus will present transfusion research at the AABB Annual Meeting in Atlanta, Oct. 17-19, 2026.
  • Oral presentations will address platelet bacterial contamination on Oct. 17 and compare pathogen-reduced versus conventional cryoprecipitate in liver transplantation on Oct. 19.
  • An Oct. 18 workshop will examine Grady Health System's real-world experience implementing INTERCEPT Platelets and INTERCEPT Fibrinogen Complex.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261014682249) on October 14, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk